Pharmaceutical Giants Slam Trump’s Upcoming Drug Pricing Plan

WASHINGTON — President Donald Trump’s initiative to revise drug pricing is already stirring substantial backlash from the pharmaceutical sector. His executive order, anticipated to be signed on Monday, aims to align medication costs for Medicare with the lowest prices from other countries.

Trump asserts that this “MOST FAVORED NATION’S POLICY” will dramatically reduce drug prices for American consumers. He emphasized this commitment in a social media post, declaring that the U.S. will pay what the lowest-priced nation values its medications.

However, the pharmaceutical industry has emerged vocally against this plan. Industry leaders warn that such measures could jeopardize research and development funding essential for new drug innovations. Stephen J. Ubl, president and CEO of PhRMA, criticized the proposal as detrimental to American patients and claimed it could undermine billions in Medicare funding.

Trump’s push for the “most favored nation” pricing model has faced scrutiny since his first term. His previous attempt to implement similar changes was halted by a court after he signed an executive order shortly before leaving office. This move has intensified debate over the potential risks of allowing foreign benchmarks to influence U.S. medication pricing.

The executive order is expected primarily to affect drugs covered by Medicare Part B, which includes those administered in a doctor’s office. Medicare users often incur out-of-pocket expenses for these treatments, and as of 2021, spending on Medicare Part B drugs reached over $33 billion.

While Trump has touted the announcement as a major fiscal relief for taxpayers, skepticism abounds regarding the actual financial benefits for individuals. The savings may be constrained to specific medications, such as cancer treatments, arguably not delivering the sweeping reductions he envisions.

Trump’s recent remarks echoed his long-standing grievances against pharmaceutical companies. He criticized their lobbying power and financing strategies, implying they disproportionately burden Americans while benefiting from research subsidies. His commitment to reform, he claims, is a step toward rectifying these systemic issues.

As discussions on drug pricing persist, the broader public sentiment criticizes the U.S.’s high medication costs compared to other nations. Despite bipartisan acknowledgment of this issue, concrete solutions have yet to materialize within Congress.

The implications of Trump’s forthcoming order remain to be seen, but both supporters and opponents are closely monitoring the situation as it develops.

Copyright 2025 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.